Frontiers in Pharmacology | Pharmacology of Anti-Cancer Drugs

Original Research

Published on 15 Aug 2025

Real-world study on adverse drug reactions of pembrolizumab in endometrial cancer treatment: insights from the FAERS database

in Pharmacology of Anti-Cancer Drugs

Huiping Zhang
Man Di
Jingjing Wang
Shan Wang
Yini Dai
Jingjing Huang
Zhuo Zhou

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1622339

454 views

Brief Research Report

Published on 15 Aug 2025

MYC target gene activation in chronic lymphocytic leukemia and richter transformation: links to aggressiveness and tumor microenvironment interactions

in Pharmacology of Anti-Cancer Drugs

M. Tsagiopoulou
S. Rashmi
M. Chatziaslani
I. Gut

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1642458

406 views

Original Research

Published on 15 Aug 2025

2H-1,4-Benzoxazin-3(4H)-one linked 1,2,3-triazole derivatives and their study on inducing DNA damage in tumor cells

in Pharmacology of Anti-Cancer Drugs

Xixi Hou
Yajie Guo
Xi Wang
En Gao
Jianxue Yang

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1564090

570 views

Original Research

Published on 15 Aug 2025

Identification of biomarkers based on ubiquitin-correlated genes for predicting immune profile and drug sensitivity in lung adenocarcinoma

in Pharmacology of Anti-Cancer Drugs

Yue Li
Wei Tian
Chen Chen
Hailin Liu
Zhenfa Zhang
Changli Wang

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1646396

243 views

Mini Review

Published on 14 Aug 2025

Drug-tolerant persister cell in cancer: reversibility, microenvironmental interplay, and therapeutic strategies

in Pharmacology of Anti-Cancer Drugs

Haifeng Li
Wenlong Xu
Wenqi Cheng
Guanxiao Yu
Dongmei Tang

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1612089

404 views

Original Research

Published on 14 Aug 2025

FGFC1 overcomes Ara-C resistance in acute myeloid leukemia by inducing apoptosis and pyroptosis

in Pharmacology of Anti-Cancer Drugs

Xiaohui Hu
Zhijian Li
Rui Zhou
Bing Zhang
Ruoxian Wang
Tongtong Li
Jiangcheng Chang
Wenhui Wu
Ning Liu

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1584376

410 views

Systematic Review

Published on 14 Aug 2025

Comparative analysis of first-generation epidermal growth factor receptor inhibitors combined with chemotherapy versus third-generation epidermal growth factor receptor inhibitors in the treatment of advanced non-small cell lung cancer: a systematic review and meta-analysis

in Pharmacology of Anti-Cancer Drugs

Siyan Peng
Zhixin Yu
Honglin Zhu
Chuwen Liang
Huijuan Qiu
Shaodong Hong
Yixin Zhou

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1586332

326 views

Editorial

Accepted on 13 Aug 2025

Editorial: Regulated Cell Death (RCD) in Cancer -Signaling Pathways Activated by Natural Products and Their Nanoformulations

in Pharmacology of Anti-Cancer Drugs

Immacolata Faraone
Rocchina Miglionico
Daniela Russo

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1679405

120 views

Review

Accepted on 13 Aug 2025

Emerging opportunities to treat drug-resistant breast cancer: Discovery of novel small-molecule inhibitors against different targets

in Pharmacology of Anti-Cancer Drugs

Ruixian Chen
Zhilan Zhou
Xiangyue Meng
Yi Lei
Yuxi Wang
Yanyan Wang

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1578342

145 views

Case Report

Published on 13 Aug 2025

Case Report: Immune-related eruptive keratoacanthoma with fungal coinfection under PD-1 inhibitor therapy: a diagnostic and therapeutic challenge

in Pharmacology of Anti-Cancer Drugs

Ying-Jie Su
Zheng Wu
Yan-Li Hou
Meng-Xia Yan
Xiu-Mei Ma
Hou-Wen Lin

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1619450

300 views

Data Report

Published on 13 Aug 2025

OncoAID: an open access targeted anti-cancer drugs database

in Pharmacology of Anti-Cancer Drugs

Ohad Landau
Shai Magidi
Catherine Bresson
Fanny Wunder
Razelle Kurzrock
Wafik S. El-Deiry
Kartheeswaran Thangathurai
Eitan Rubin

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1588191

972 views

Correction

Published on 13 Aug 2025

Correction: Current paradigm and futuristic vision on new-onset diabetes and pancreatic cancer research

in Pharmacology of Anti-Cancer Drugs

Russell Moreland
Abigail Arredondo
Anupam Dhasmana
Swati Dhasmana
Shabia Shabir
Asfia Siddiqua
Bonny Banerjee
Murali M. Yallapu
Stephen W. Behrman
Subhash C. Chauhan

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1662270

240 views

Original Research

Published on 13 Aug 2025

Mechanisms of sorafenib-induced cardiotoxicity: ER stress induces upregulation of ATF3, leading to downregulation of NDUFS1 expression and mitochondrial dysfunction

in Pharmacology of Anti-Cancer Drugs

Ming Yan
Cheng Peng
Xueyan Lang
Yilan Li
Yao Zhang

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1593290

496 views

Original Research

Accepted on 12 Aug 2025

Phytochemical Combinations of Lichen Evernia prunastri (L.) Ach reduce Drug Resistance to Temozolomide but not to Paclitaxel in vitro

in Pharmacology of Anti-Cancer Drugs

Anastasiia Shcherbakova
Linh Nguyen
Anna Koptina
Anders Backlund
Subhadip Banerjee
Evgeniy Romanov
Gudrun S. Ulrich-Merzenich

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1633978

130 views

Review

Accepted on 12 Aug 2025

ACSL4 at the Helm of the Lipid Peroxidation Ship: A Deep-Sea Exploration Towards Ferroptosis

in Pharmacology of Anti-Cancer Drugs

Yulang Jiang
Meng Zhang
Mingyu Sun

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1594419

105 views

Review

Published on 12 Aug 2025

Indoleamine 2,3-dioxygenase 1 in cancer immunotherapy: from small-molecule inhibition to PROTAC-mediated degradation

in Pharmacology of Anti-Cancer Drugs

Xiuyun Li
Hao Meng
Hefeng Wang
Yujing Zhang
Wanpeng Yu

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1640073

429 views